ClinicalTrials.gg
CompletedNCT01722318CIBSUpdated May 28, 2019Results posted

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

A Phase 2 interventional study of Plecanatide and Placebo in Irritable Bowel Syndrome Characterized by Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 99 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-28.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
8th of 12
428 · median 800
Started
2012
the only one that year
Phase 2
5 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 5 in phase 2, and was the 3rd registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.

Read the detailed description

This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C. Patients will undergo a Screening Period to determine eligibility. After completing a Screening Visit patients will undergo a 2-week Pre-Treatment assessment using the Interactive Voice Response System (IVRS) during which they will complete daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale- BSFS), abdominal pain or abdominal discomfort and other symptoms associated with IBS-C. Data from the two-week IVRS Pre-treatment assessment are used to define the patient's baseline from which change will be determined. Patients who meet all entry criteria will be randomized to one of five treatment groups ( 0.3mg,1.0mg,3.0mg,9mg,or Placebo) on Day 1 of the Treatment Period. Patients will take an oral dose of study drug daily (QD) for 12 weeks and continue the daily IVRS diaries (BMs, abdominal pain, other symptoms). On Weeks 2, 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments. For 2 weeks after completing dosing, (i.e., Post-Treatment Period), patients will continue to complete daily IVRS diaries. Patients will then return to the clinical site for a final follow-up visit (End of Study Visit). The planned duration of participation in this study will be approximately 112 days from signing of informed consent through post-treatment or 145 days if 30 day washout of a prohibited concomitant medication or stabilization of a medical condition is required before Pre-Treatment (up to 148 days, with all windows considered).

03

Conditions studied

  • Irritable Bowel Syndrome Characterized by Constipation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-75, inclusive
  • = 18-35 kg/m2, inclusive
  • Meets modified Rome III criteria for irritable bowel syndrome with constipation which includes abdominal pain or discomfort for at least 3 days/month in the last 3 months with symptom onset for at least 6 months.
  • Less than 3 CSBMs and less than 6 SBMs per week during the last 3 months.
  • Hard or lumpy stools ≥ 25 % of defecations
  • Patient has average abdominal pain intensity scores ≥ 3 (scale 0-10)for the combined 2 week pre-treatment period
  • Patient is willing to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods
  • Willing to maintain a stable diet during the study.
  • Patients with hemorrhoids and/or diverticulosis (NOT diverticulitis) CAN be entered into the study.

Exclusion criteria

Exclusion Criteria:

  • Loose stool (mushy) or watery stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day pre-treatment period
  • Patient has diarrhea-predominant or mixed ( diarrhea and constipation cycling or diarrhea and normal cycling) IBS.
  • Active peptic ulcer disease not adequately treated or not stable
  • History of cathartic colon, laxative, enema abuse, or ischemic colitis.
  • Fecal impaction within 3 months of screening
  • Patient has had /has any: structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
  • Unexplained and "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis.
  • Major surgery within 60 days of screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
428 participants (actual)

Study arms

  • Active comparator
    Plecanatide 0.3mg

    Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    Plecanatide 1.0mg

    Plecanatide 1.0mg one tablet by mouth daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    Plecanatide 3.0mg

    Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    Plecanatide 9.0mg

    Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks

    Drug: Plecanatide

  • Placebo comparator
    Placebo

    Placebo, one tablet by mouth daily for 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population)

    The primary efficacy endpoint was the change from baseline in the weekly CSBM frequency (CSBMs per week minus CSBMs per week at baseline) over a 12-week Treatment Period. A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation.

    Time frame: 12 weeks Treatment Period

Secondary outcomes

  1. Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population)

    Abdominal Pain was assessed in the patient's daily response on a scale of 0 to 10 where 0 is did not experience the symptom at all and 10 is experienced the worst.

    Time frame: 12-Week Treatment Period

  2. Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population)

    The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

    Time frame: 12-Week Treatment Period

  3. Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population)

    The severity of straining (Straining Score) was rated by the patients using a 11-point scale (0-10) where 0 = none and 10 = very severe

    Time frame: 12-Week Treatment Period

07

Results

Posted Sep 17, 2018

Participant flow

Participant flow — Overall Study
MilestonePlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
Started8685868586
Completed7265666568
Not completed1420202018

Outcome measures

PrimaryChange From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population)

The primary efficacy endpoint was the change from baseline in the weekly CSBM frequency (CSBMs per week minus CSBMs per week at baseline) over a 12-week Treatment Period. A Complete Spontaneous Bowel Movement (CSBM) is a Bowel Movement (BM) that occurs in the absence of laxative use within 24 hours of the BM and the patient reports a feeling of complete evacuation.

Time frame:
12 weeks Treatment Period
Reported as:
Least squares mean · CSBMs per week
Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population)
CSBMs per weekPlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population)1.28 ± 0.2602.12 ± 0.2652.74 ± 0.2602.44 ± 0.2621.27 ± 0.260
SecondaryChange From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population)

Abdominal Pain was assessed in the patient's daily response on a scale of 0 to 10 where 0 is did not experience the symptom at all and 10 is experienced the worst.

Time frame:
12-Week Treatment Period
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population)
scores on a scalePlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population)-1.5 ± 0.20-1.5 ± 0.20-2.0 ± 0.20-1.8 ± 0.20-1.4 ± 0.20
SecondaryChange From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population)

The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

Time frame:
12-Week Treatment Period
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population)
scores on a scalePlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population)1.63 ± 0.1431.81 ± 0.1442.49 ± 0.1432.24 ± 0.1451.01 ± 0.143
SecondaryChange From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population)

The severity of straining (Straining Score) was rated by the patients using a 11-point scale (0-10) where 0 = none and 10 = very severe

Time frame:
12-Week Treatment Period
Reported as:
Least squares mean · score on a scale
Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population)
score on a scalePlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population)-1.7 ± 0.23-1.5 ± 0.23-2.2 ± 0.23-2.1 ± 0.24-1.3 ± 0.23

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Plecanatide 0.3mg—1/85 (1.2%)18/85 (21.2%)
Plecanatide 1.0mg—0/85 (0%)29/85 (34.1%)
Plecanatide 3.0mg—1/86 (1.2%)19/86 (22.1%)
Plecanatide 9.0mg—2/85 (2.4%)31/85 (36.5%)
Placebo—0/86 (0%)12/86 (14%)
Most frequent serious events
Most frequent serious events
EventPlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
AppendicitisInfections and infestations1/850/850/860/850/86
Bile duct stoneHepatobiliary disorders0/850/850/861/850/86
Supraventricular tachycardiaCardiac disorders0/850/850/861/850/86
Cholecystitis acuteHepatobiliary disorders0/850/851/860/850/86
Most frequent other events
Most frequent other events
EventPlecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlacebo
DiarrhoeaGastrointestinal disorders3/858/858/8610/850/86
HeadacheNervous system disorders2/855/853/868/854/86
Urinary tract infectionInfections and infestations1/855/853/861/851/86
NauseaGastrointestinal disorders4/851/852/864/855/86
Back painMusculoskeletal and connective tissue disorders1/854/850/862/850/86
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders3/853/850/861/851/86
Upper Respiratory Tract InfectionInfections and infestations2/852/851/863/851/86
FatigueGeneral disorders2/851/852/862/850/86

Baseline characteristics

The Randomized Population (428 patients) in Participant Flow differs from the mITT Population (423 patients) because 1 patient was randomized and not dosed, 1 patient was dosed but had no post-baseline efficacy assessments, and 3 duplicate patient records (2 patients who were seen at 2 sites and 1 patient who was seen at 3 sites)

Age, Continuous
Age, Continuous(years)Plecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlaceboTotal
Mean47.2 ± 12.0244.6 ± 12.5847.2 ± 12.8945.3 ± 12.0045.4 ± 12.0245.9 ± 12.30
Sex: Female, Male
Sex: Female, Male(Participants)Plecanatide 0.3mgPlecanatide 1.0mgPlecanatide 3.0mgPlecanatide 9.0mgPlaceboTotal
Female6867707069344
Male161616151679
08

Study locations

99 sites
  • Cahaba Research
    Birmingham, Alabama 35242, United States
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Arrowhead Family Health Center PC dba Arrowhead Health Centers
    Glendale, Arizona 85306, United States
  • Advanced Research Associates, LLC
    Glendale, Arizona 85308, United States
  • Elite Clinical Trials, LLC
    Phoenix, Arizona 85018, United States
  • Genova Clinical Research, Inc.
    Tucson, Arizona 85704, United States
  • Adobe Clinical Research, LLC
    Tucson, Arizona 85712, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72205, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Advanced Rx Clinical Research, Inc.
    Artesia, California 90701, United States
  • GW Research, Inc.
    Chula Vista, California 91910, United States
  • SC Clinical Research, Inc.
    Garden Grove, California 92844, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Community Clinical Trials
    Orange, California 92868, United States
  • Healthcare Partners Medical Group
    Pasadena, California 91105, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Memorial Research Medical Clinic d/b/a Orange Country Research Center
    Tustin, California 92780, United States
  • Lynn Institute of the Rockies
    Colorado Springs, Colorado 80907, United States
  • Horizons Clinical Research Center, LLC
    Denver, Colorado 80220, United States
  • Consultants for Clinical Research of South Florida
    Boynton Beach, Florida 33426, United States
  • Medical Research Unlimited, LLC
    Hialeah, Florida 33012, United States
  • Eastern Research, Inc
    Hialeah, Florida 33013, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Jupiter Research, Inc.
    Jupiter, Florida 33458, United States
  • MNH Surgical Center
    Maitland, Florida 32751, United States
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33015, United States
  • Genoma Research Group, Inc.
    Miami, Florida 33165, United States
  • Columbus Clinical Services, LLC
    Miami, Florida 33174, United States
  • South Medical Research Group, Inc.
    Miami, Florida 33186, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Urology Center of Florida
    Pompano Beach, Florida 33060, United States
  • Accord Clinical Research, LLC
    Port Orange, Florida 32129, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Mount Vernon Clinical Research, LLC
    Sandy Springs, Georgia 30328, United States
  • CTL Research
    Eagle, Idaho 83616, United States
  • Medex Healthcare Research, Inc
    Chicago, Illinois 60602, United States
  • Rockford Gastroenterology Associates
    Rockford, Illinois 61107, United States
  • Heartland Research Associates, LLC
    Augusta, Kansas 67010, United States
  • Research Integrity, LLC
    Owensboro, Kentucky 42303, United States
  • Delta Research Partners, LLC
    Bastrop, Louisiana 71220, United States
  • Gastroenterology Research of New Orleans
    Hammond, Louisiana 70403, United States
  • Centex Studies, Inc.
    Lake Charles, Louisiana 70601, United States
  • Women Under Study, LLC
    New Orleans, Louisiana 70115, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71103, United States
  • MGG Group Co., Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Novex Clinical Research, LLC
    New Bedford, Massachusetts 02740, United States
  • Bay State Clinical Trials, Inc.
    Watertown, Massachusetts 02472, United States
  • IHA Chelsea Family & Internal Medicine
    Chelsea, Michigan 48118, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Ridgeview Research
    Chaska, Minnesota 55318, United States
  • Prism Research
    Saint Paul, Minnesota 55114, United States
  • The Center for Clinical Trials
    Biloxi, Mississippi 39531, United States
  • Gastrointestinal Associates, PA
    Jackson, Mississippi 39202, United States
  • St. Louis Center for Clinical Research
    Saint Louis, Missouri 63128, United States
  • Montana Health Research Institute, Inc.
    Billings, Montana 59102, United States
  • Internal Medical Associates of Grand Island, PC
    Grand Island, Nebraska 68803, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • St. Luke's Hospital
    New York, New York 10025, United States
  • Asheville Gastroenterology Associates, PA
    Asheville, North Carolina 28801, United States
  • MediSpect Medical Research, LLC
    Boone, North Carolina 28607, United States
  • Clinical Trials of North Carolina, LLC
    Cary, North Carolina 27518, United States
  • Carolina Digestive Health Associates
    Charlotte, North Carolina 28210, United States
  • On Site Clinical, LLC
    Charlotte, North Carolina 28277, United States
  • Carolina Digestive Health Associates
    Davidson, North Carolina 28036, United States
  • Cumberland Research Associates, LLC
    Fayetteville, North Carolina 28304, United States
  • LeBauer Research Associates, P.A.
    Greensboro, North Carolina 27403, United States
  • Medoff Medical / Vital re:Search
    Greensboro, North Carolina 27408, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • PMG Research of Winston-Salem, LLC
    Winston-Salem, North Carolina 27103, United States
  • Hometown Urgent Care and Occupational Health
    Columbus, Ohio 43214, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Oklahoma Foundation for Digestive Research
    Oklahoma City, Oklahoma 73104, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Options Health Research, LLC
    Tulsa, Oklahoma 74104, United States
  • Consultants in Gastroenterology
    Columbia, South Carolina 29203, United States
  • Southeast Medical Research
    North Charleston, South Carolina 29406, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Chattanooga Medical Research LLC
    Chattanooga, Tennessee 37404, United States
  • ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Franklin Gastroenterology, PLLC
    Franklin, Tennessee 37067, United States
  • Memphis Gastroenterology Group, PC
    Germantown, Tennessee 38138, United States
  • Associates in Gastroenterology
    Hermitage, Tennessee 37076, United States
  • Austin Center for Clinical Research
    Austin, Texas 78756, United States
  • DCT-AACT, LLC dba Discovery Clinical Trials
    Austin, Texas 78758, United States
  • Texas Tech Medical Center
    El Paso, Texas 79905, United States
  • Centex Studies, Inc.
    Houston, Texas 77062, United States
  • North Texas Family Medicine
    Plano, Texas 75093, United States
  • Quality Research, Inc.
    San Antonio, Texas 78209, United States
  • Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute
    San Antonio, Texas 78228, United States
  • Pioneer Research Solutions, Inc.
    Sugar Land, Texas 77479, United States
  • New River Valley Research Institute
    Christiansburg, Virginia 24073, United States
  • Blue Ridge Medical Research/Gastroenterology Associates of Central Virginia
    Lynchburg, Virginia 24502, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Apr 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2012
First posted
Nov 6, 2012
Start
Nov 2012
Primary completionActual
Apr 2014
CompletionActual
Oct 2014
Results first posted
Sep 17, 2018
Last update
May 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01722318
Responsible party
Sponsor
First posted
Nov 6, 2012
Start date
Nov 2012
Primary completion
Apr 2014
Completion
Oct 2014
Results posted
Sep 17, 2018
Last update
May 28, 2019

Study contacts

Philip B Miner, MD
principal investigator · Oklahoma Foundation for Digestive Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion